Subtype
Malignant Urinary Tract Neoplasm
CI-CAN-00003252Explore in graph →
507 active trials14 approved drugs29 evidence items
- NCIt
- C192668
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003252Explore in graph →
Clinical trials
1,954 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (246)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05229614 | Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease(ICONIC) | unknown | Phase 2 | 27 | CNAO National Center of Oncological HadrontherapyOTHER | 2 | Aug 21, 2024 | clinicaltrials |
| NCT04486781 | A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma | unknown | Phase 2 | 38 | Vasgene Therapeutics, IncINDUSTRY | 1 | May 2, 2024 | clinicaltrials |
| NCT03549715 | NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma(NEMIO) | unknown | Phase 1 / Phase 2 | 121 | Association Pour La Recherche des Thérapeutiques Innovantes en CancérologieOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT04492293 | An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer | unknown | Phase 2 | 115 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Feb 26, 2024 | clinicaltrials |
| NCT05297552 | A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer | unknown | Phase 2 | 40 | RemeGen Co., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03924466 | Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients(VUBAR) | unknown | Phase 2 | 55 | Universitair Ziekenhuis BrusselOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT06221774 | Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors | unknown | Phase 1 / Phase 2 | 42 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT06178601 | A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma | unknown | Phase 2 | 36 | Shanxi Province Cancer HospitalOTHER | 1 | Dec 21, 2023 | clinicaltrials |
| NCT02969083 | Feasibility of Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma(URANUS) | unknown | Phase 2 | 200 | The European Uro-Oncology GroupOTHER | 3 | Dec 18, 2023 | clinicaltrials |
| NCT06074484 | A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer | unknown | Phase 2 | 36 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT05975151 | Efficacy and Safety of Pseudomonas Aeruginosa for Intermediate and High-risk Non-muscle Invasive Bladder Cancer | unknown | Phase 2 | 63 | Qilu Hospital of Shandong UniversityOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06009848 | Cadonilimab Plus Nab-Paclitaxel for Recurrent or Metastatic Muscle Invasive Bladder Cancer | unknown | Phase 2 | 20 | Tianjin Medical University Second HospitalOTHER | 1 | Aug 24, 2023 | clinicaltrials |
| NCT05912205 | Disitamab Vedotin Combined With Radiotherapy for Bladder Preservation | unknown | Phase 2 | 30 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Jun 22, 2023 | clinicaltrials |
| NCT05895864 | Utidelone Treated for the Recurrent or Metastatic Urothelial Carcinoma | unknown | Phase 2 | 34 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT05823246 | Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma | unknown | Phase 2 | 66 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 26, 2023 | clinicaltrials |
| NCT04543110 | Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC(RADIANT) | unknown | Phase 2 | 16 | Ottawa Hospital Research InstituteOTHER | 1 | Mar 23, 2023 | clinicaltrials |
| NCT05775874 | A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC | unknown | Phase 2 | 80 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Mar 20, 2023 | clinicaltrials |
| NCT04565275 | A Study of ICP-192 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 45 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 2 | Mar 14, 2023 | clinicaltrials |
| NCT05429866 | Immunological Variables Associated to ICI Toxicity in Cancer Patients | unknown | Phase 2 | 441 | Jules Bordet InstituteOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors(REGOMUNE) | unknown | Phase 1 / Phase 2 | 747 | Institut BergoniéOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT04799847 | Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG Vaccine | unknown | Phase 1 / Phase 2 | 161 | LintonPharm Co.,Ltd.INDUSTRY | 1 | Feb 13, 2023 | clinicaltrials |
| NCT04730219 | Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma | unknown | Phase 2 | 48 | Tianjin Medical University Second HospitalOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT03529890 | Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the Bladder(RACE IT) | unknown | Phase 2 | 33 | Technical University of MunichOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT05564897 | Oncolytic Adenovirus Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder Cancer | unknown | Phase 2 | 25 | Zhejiang Cancer HospitalOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT05038657 | Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC).(AURORA) | unknown | Phase 2 | 36 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Oct 3, 2022 | clinicaltrials |
| NCT03844256 | A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study(CRIMI) | unknown | Phase 1 / Phase 2 | 50 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Aug 12, 2022 | clinicaltrials |
| NCT03827837 | Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors | unknown | Phase 2 | 265 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 1, 2022 | clinicaltrials |
| NCT03062059 | The Effectiveness and Safety of Intravesical Gemcitabine Instillation to Prevent Intravesical Recurrence | unknown | Phase 2 | 134 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 14, 2022 | clinicaltrials |
| NCT04876313 | An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo)(NURE-Combo) | unknown | Phase 2 | 29 | IRCCS San RaffaeleOTHER | 1 | Apr 6, 2022 | clinicaltrials |
| NCT03759496 | Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer | unknown | Phase 2 | 39 | Hellenic GenitoUrinary Cancer GroupOTHER | 1 | Mar 23, 2022 | clinicaltrials |
| NCT03993249 | Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy | unknown | Phase 2 | 78 | Hellenic GenitoUrinary Cancer GroupOTHER | 1 | Mar 23, 2022 | clinicaltrials |
| NCT03762161 | A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer | unknown | Phase 2 | 22 | Rahul ParikhOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT02535650 | Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma | unknown | Phase 2 | 19 | Samsung Medical CenterOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT05108077 | Treatment of Metastatic Tumors of the Urogenital Area With Cytokine-induced Killer Cells | unknown | Phase 1 / Phase 2 | 20 | Institute of Biophysics and Cell Engineering of National Academy of Sciences of BelarusOTHER_GOV | 1 | Jan 14, 2022 | clinicaltrials |
| NCT03715985 | Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)(NeoPepVac) | unknown | Phase 1 / Phase 2 | 12 | Herlev HospitalOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT05160285 | Neoadjuvant Nivolumab for Upper Tract Urothelial Carcinoma | unknown | Phase 2 | 29 | YULISUOTHER | 1 | Dec 16, 2021 | clinicaltrials |
| NCT04839510 | A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer | unknown | Phase 2 | 58 | Shanghai Miracogen Inc.INDUSTRY | 1 | Dec 14, 2021 | clinicaltrials |
| NCT04730232 | Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable | unknown | Phase 2 | 63 | Tianjin Medical University Second HospitalOTHER | 1 | Oct 29, 2021 | clinicaltrials |
| NCT05086666 | A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547 | unknown | Phase 1 / Phase 2 | 108 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Oct 21, 2021 | clinicaltrials |
| NCT05030077 | Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma | unknown | Phase 2 | 53 | Tianjin Medical University Second HospitalOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT05016973 | A Clinical Study of RC48-ADC Combined With Triplizumab For Treatment of Myometrial Invasive Bladder Cancer | unknown | Phase 2 | 25 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Aug 23, 2021 | clinicaltrials |
| NCT05001763 | Prucalopride for Postoperative Ileus in Patients Undergoing Robot-assisted Laparoscopic Radical Cystectomy | unknown | Phase 2 | 160 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Aug 12, 2021 | clinicaltrials |
| NCT04909775 | Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer | unknown | Phase 2 | 40 | Ruijin HospitalOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT04878250 | Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the Bladder(PEBBLE) | unknown | Phase 2 | 49 | Queen Mary University of LondonOTHER | 0 | May 7, 2021 | clinicaltrials |
| NCT03824691 | hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"(ARCADIA) | unknown | Phase 2 | 122 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Feb 25, 2021 | clinicaltrials |
| NCT04383067 | A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients | unknown | Phase 2 | 20 | Sheba Medical CenterOTHER_GOV | 1 | Feb 11, 2021 | clinicaltrials |
| NCT04738630 | Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer | unknown | Phase 2 | 110 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | Feb 4, 2021 | clinicaltrials |
| NCT04211012 | A Study on Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Urothelial Carcinoma | unknown | Phase 2 | 30 | Jun GuoOTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT03113266 | Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma | unknown | Phase 2 | 370 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Sep 30, 2020 | clinicaltrials |
| NCT04493489 | Propranolol Adjuvant Treatment of Bladder Cancer | unknown | Phase 2 | 242 | Central South UniversityOTHER | 0 | Jul 30, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Aug 21, 2024source: clinicaltrials